Product Images Fluzone Quadrivalent Northern Hemisphere

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Fluzone Quadrivalent Northern Hemisphere NDC 49281-629 by Sanofi Pasteur Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Package - fluzone 01

PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Package - fluzone 01

This is a description of Fluzone® Quadrivalent, an influenza vaccine that is administered through injection only. It comes in single-dose vials with no preservatives and contains the 2022-2023 formula, manufactured by Sanofi Pasteur Inc. The product's NDC number is 49281-422-58.*

PRINCIPAL DISPLAY PANEL - 0.25 mL Syringe Package - fluzone 02

PRINCIPAL DISPLAY PANEL - 0.25 mL Syringe Package - fluzone 02

This is a description of Fluzone Quadrivalent, an influenza vaccine that is administered through an intra-muscular injection. The vaccine contains influenza viruses that have been standardized to meet the requirements set by the USPHS for the 2022-2023 flu season. The vaccine formulation contains 60 micrograms of hemagglutinin (HA) per 0.5 mL dose. Fluzone Quadrivalent meets the ratio of 15 micrograms of HA each that are representative of prototype strains A/Victoria/2570/2019 IVR-215 (H1N1), A/Darwin/9/2021 SAN-010 (H3N2), B/Phuket/3073/2013 (B Yamagata lineage), and B/Michigan/01/2021 (2 B/Austria/1359417/2021-like virus, B Victoria lineage). The vaccine does not contain any preservatives or natural rubber latex. It is produced through propagation of the virus in embryonated chicken eggs and is inactivated using formaldehyde. It should be stored at 2°C to 8°C (35°F to 46°F). Any unused portion must be discarded per the manufacturer's instructions. Full prescribing information is available for additional details.*

PRINCIPAL DISPLAY PANEL - 5 mL Vial Package - fluzone 03

PRINCIPAL DISPLAY PANEL - 5 mL Vial Package - fluzone 03

This is a description of a flu vaccine called Fluzone Quadrivalent that is administered via intramuscular injection. The lot number, expiry date, NDC number, and manufacturer (Sanofi Pasteur Inc.) are all provided. The vaccine is preservative-free and is formulated for the 2022-2023 flu season. However, part of the text is not readable or contains non-English characters.*

fluzone 04

fluzone 04

This is a description of the Fluzone Quadrivalent Influenza Vaccine manufactured by Sanofi Pasteur Inc. The vaccine is for individuals who are 6 months of age or older and should be administered through intramuscular injection. The vaccine contains 60 micrograms of hemagglutinin per 0.5 ml dose, which is representative of the Yamagata and B/Michigan/0/2015 lineages. The vaccine is standardized according to USPHS requirements for the 2022-2023 influenza season. It comes in 10 single-dose prefilled syringes, not made with natural rubber latex and should not be frozen; it should be stored between 2°C and 8°C (35°F and 46°F). The description also includes the NDC number (49281-422-50), and the TN (0345281422508).*

fluzone 05

fluzone 05

This is a description of the Fluzone® Quadrivalent Influenza Vaccine manufactured by Sanofi Pasteur Inc. The vaccine is for individuals six months and older and is given via intramuscular injection. It should not be frozen and must be stored between 2°C and 8°C. The vaccine has been prepared using influenza viruses grown in embryonated chicken eggs and inactivated with formakdehyde. It contains no natural rubber latex. The vaccine is standardized to contain 60 micrograms of hemagglutinin and is formulated to be effective against the influenza strains expected for the 2022-2023 season. For additional information, refer to the prescribing information.*

fluzone 06

fluzone 06

The text describes an Influenza Vaccine, Fluzone, that comes in a 5 mL Multi-Dose Vial. It contains a preservative and is designed as a Quadrivalent vaccine. The product should not be frozen and must be stored between 2°C to 8°C (35°F to 46°F). The vaccine is intended for intramuscular injection and can be obtained under US Govt License #1725. It is manufactured by Sanofi Pasteur Inc. in Swiftwater, PA. However, the characters in the text suggest that they may not be rendered correctly, and so the actual content may differ from what is visible in the text.*

fluzone 07

fluzone 07

This text provides instructions and information about the Fluzone Quadrivalent influenza vaccine manufactured by Sanof Pasteur Inc. It should not be frozen and should be stored at 2° to 8°C. The vaccine has been standardized for the 2022-2023 influenza season and contains hemagglutinin representative of certain prototype strains. The vaccine is for intramuscular injection only and not made with natural rubber latex. Each dose contains the preservative thimerosal, and the full prescribing information should be referenced for additional details.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.